Sangamo sells ST-920 Fabry gene therapy to PTC for $111M cash plus $100M milestones in Chapter 11

SANGAMO THERAPEUTICS, INC

Sangamo filed Chapter 11 on June 23, 2026; PTC won auction for ST-920 assets.
Deal: $111M cash at closing plus up to $100M milestones; $80M on FDA accelerated approval, $20M on full approval.
Bankruptcy Court hearing to approve sale scheduled for September 10, 2026; closing by October 15, 2026.
ST-920 is AAV gene therapy for Fabry disease; PTC assumes specified liabilities.
Stock delisted from Nasdaq May 5, 2026; now trades OTC as SGMOQ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.